Peptides based on the sequence of human lactoferrin and their use
View Patent ↗The invention relates to new peptides formed of at least seven subsequent amino acids of the amino acids in position 12-40, counted from the N-terminal end, in the sequence constituting human lactoferrin, and preferably modifications thereof. The invention also relates to medicinal products comprising such peptides, especially intended for treatment and prevention of infections, inflammations and tumours. Furthermore, the invention relates to food stuff, e.g. infant formula food, comprising the above mentioned peptides.
1. A purified peptide comprising 20 Cys-Phe-X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -Lys-Val-Arg 31 (SEQ ID NO: 99) wherein X 1 is Gln, or Ala; X 2 is Trp or Leu; X 3 is Gln, Lys, Orn, Ala, or Nle; X 4 is Arg, Lys, Ala; X 5 is Asn, Orn, Ala, or Nle; X 6 is Met or Leu; and X 7 is Arg or Lys, and wherein the peptide is SEQ ID NO:2-5, 8, 31-37, 47, 49, 51, 63, 65, 67, 70, 72-74, 80-83, 87-96 or 97.
2. The purified peptide of claim 1 , wherein the peptide is SEQ ID NO: 70, 72, 73, 74, 80-83, 87-91, 93-95 or 97.
3. The purified peptide of claim 2 , wherein the peptide is SEQ ID NO: 70 or 74.
4. The purified peptide of claim 2 , wherein the peptide is SEQ ID NO: 81 or 83.
5. The purified peptide of claim 2 , wherein the peptide is SEQ ID NO: 87 or 89.
6. The purified peptide of claim 2 , wherein the peptide is SEQ ID NO: 91.
7. A medicinal product comprising a peptide of claim 2 .
8. A method of treating infections or inflammations comprising administering to a patient in need thereof an amount of a peptide of claim 2 , wherein the amount of peptide is effective to reduce infections or inflammations.
9. The purified peptide of claim 1 , wherein the peptide is SEQ ID NO: 47 or 92.
10. A medicinal product comprising a peptide of claim 1 .
11. The medicinal product of claim 10 formulated for parenteral administration.
12. The medicinal product of claim 10 formulated for oral administration.
13. The medicinal product of claim 10 formulated for topical administration.
14. The medicinal product of claim 13 formulated for administration on mucosal membranes.
15. A food stuff comprising a peptide of claim 1 .
16. The food stuff of claim 15 , wherein the food stuff is an infant formula food.
17. A method of treating infections or inflammations comprising administering to a patient in need thereof an amount of a peptide of claim 1 , wherein the amount of peptide is effective to reduce infections or inflammations.
18. The method of claim 17 , wherein the infection is a urinary tract infection.
19. The method of claim 17 , wherein the inflammation or infection is colitis.
20. The method of claim 17 , wherein the infection is a candida infection on a mucosal membrane.
21. The method of claim 17 , wherein the peptide is administered orally.
22. The method of claim 21 , wherein the peptide is administered orally in a food stuff.
23. The method of claim 22 , wherein food stuff is an infant formula food.
24. The method of claim 17 , wherein the peptide is administered parenterally.
25. The method of claim 17 , wherein the peptide is administered topically.
26. The method of claim 25 , wherein the peptide is administered on mucosal membranes.
27. The purified peptide of claim 1 , wherein the peptide is SEQ ID NO:2-4 or 5.
28. A medicinal product comprising a peptide of claim 27 .
29. A method of treating infections or inflammations comprising administering to a patient in need thereof an amount of a peptide of claim 27 , wherein the amount of peptide is effective to reduce infections or inflammations.
30. The purified peptide of claim 1 , wherein the peptide is SEQ ID NO: 8, 31-37, 47, 49, 51, 63, 65 or 67.
31. A medicinal product comprising a peptide of claim 30 .
32. A method of treating infections or inflammations comprising administering to a patient in need thereof an amount of a peptide of claim 30 , wherein the amount of peptide is effective to reduce infections or inflammations.
33. A purified peptide comprising 20 Cys-Phe-X 1 -X 2 -X 3 -X 4 -X 5 -X 6 -X 7 -Lys-Val-Arg 31 (SEQ ID NO: 99) wherein X 1 is Gln, or Ala; X 2 is Trp or Leu; X 3 is Gln, Lys, Orn, Ala, or Nle; X 4 is Arg, Lys, Ala; X 5 is Asn, Orn, Ala, or Nle; X 6 is Met or Leu; and X 7 is Arg or Lys, wherein the peptide is SEQ ID NO:2-5, 8, 31-37, 47, 49, 51, 63, 65, 67, 70, 72-74, 80-83, 87-88 or 89, and wherein the cysteine is replaced by an acetamidomethyl-cysteine.
34. A purified peptide, comprising 20 Cys-Phe-X 1 -X 2 -X 3 -X 4 -X 5 X 6 -X 7 -Lys-Val-Arg 31 (SEQ ID NO: 99), wherein
X 1 is Gln or Ala;
X 2 is Trp or Leu;
X 3 is Gln, Lys, Orn, Ala, or Nle;
X 4 is Arg, Lys, or Ala;
X 5 is Asn, Orn, Ala, or Nle;
X 6 is Met or Leu;
X 7 is Arg or Lys;
wherein the peptide is the amino acid sequence consisting of TK or EATK (SEQ ID NO:102) at the amino acid terminus of the peptide of SEQ ID NO:70, 72, 73, 74, 80-83, 87-91, 93-95, or 97.